TMCI (Treace Medical Concepts) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TMCI Treace Medical Concepts Inc TMCI
68 GF Score
Price $4.79
GF Value $6.35
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Treace Medical Concepts Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TMCI
68GF Score
Treace Medical Concepts Inc TMCI
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Treace Medical Concepts (TMCI) Overvalued in 2026?

Based on GuruFocus' analysis, Treace Medical Concepts stock appears to be undervalued. The current stock price of $4.79 is trading 24.6% below its estimated GF Value™ of $6.35. GuruFocus considers Treace Medical Concepts to be Modestly Undervalued.

Key valuation signals for TMCI:

  • Dividends Received:
  • GF Value™: $6.35 vs. price of $4.79 (24.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the TMCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Treace Medical Concepts Business Description

Address 100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
68GF Score

Get the complete analysis for TMCI

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price
$6.35
GF Value